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Backgound: Ischemia activates late Na current and causes increased diastolic tension, which provokes more ischemia by decreasing myocardial 
blood flow (MBF). Ranolazine inhibits the late Na current and improves ischemia. Most reversible perfusion defects (RPD) during exercise represent 
ischemia, while most RPD during vasodilator stress represent mere MBF heterogeneity. We hypothesized that Ranolazine would improve ischemia 
with exercise stress but not with vasodilators, as measured by serial gated SPECT myocardial perfusion imaging (MPI).
Methods: Patients with exertional angina and a RPD on a clinically indicated MPI were re-studied 4 weeks after ranolazine (500-1000 mg PO BID) 
was added to their conventional treatment in an open-label trial; 20 patients underwent exercise while 16 had vasodilator stress (regadenoson-14 
and adenosine-2). The perfusion pattern was assessed using polar maps in a 17-segment model to derive the summed stress score (SSS), summed 
difference score (SDS) and summed rest score (SRS).
Results: The exercise group comprised of 6 women (30%) and 10 diabetics (50%), while the vasodilator group had 5 women (31%) and 8 
diabetics (50%). There was no difference in SSS or SDS at baseline in the exercise and vasodilator groups. In the exercise arm 15 patients (75%) 
showed improvement in perfusion after ranolazine, while only 3 patients (18%) in the vasodilator arm showed improvement (p=0.002). The SDS 
decreased from 7.4 ± 5.0 before to 4.7 ± 4 after treatment (P=0.003) in the exercise group but remained unchanged in the vasodilator group (6.4 
± 6 before vs. 6± 6 after treatment, P=NS). The change in the SDS accounted for the decrease in SSS in the exercise group (13.8 ± before vs. 10 ± 7 
after treatment, P=0.04) while there was no change in SSS in the vasodilator group (12.9 ± 9 before vs. 12 ± 10 after treatment, P=NS). The SRS did 
not change in either group.
Conclusions: The improvement in myocardial perfusion pattern with ranolazine is better detected with exercise stress than vasodilator stress MPI 
because exercise is more likely to provoke ischemia. This is consistent with the mechanism of action of this novel anti-anginal agent.
